Litcius/Paper detail

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates

2020Annals of Oncology482 citationsDOI

Topics & Concepts

MedicinePARP inhibitorHomologous recombinationOvarian cancerBiomarkerOncologyHomologous chromosomePoly ADP ribose polymeraseInternal medicineCancerGeneticsDNAGeneBiologyPolymerasePARP inhibition in cancer therapyDNA Repair MechanismsOvarian cancer diagnosis and treatment
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer | Litcius